Q4 EPS Estimates for Globus Medical Lifted by Zacks Research

Key Points

• Zacks Research raised its Q4 2027 EPS estimate for Globus Medical to $1.37 from $1.22 and maintained a “Strong-Buy” rating. It also projects FY2028 EPS of $5.88.
• Globus Medical’s latest quarter exceeded expectations, with EPS of $1.34 versus $1.10 expected and revenue of $789.6 million versus $782.9 million forecast; revenue increased 5.9% year over year.
• The stock has a “Moderate Buy” consensus rating and an average analyst price target of $101.77, compared with an opening price of $83.03, while institutional investors own 95.16% of shares.

Globus Medical, Inc. (NYSE:GMED - Free Report) - Equities research analysts at Zacks Research increased their Q4 2027 EPS estimates for Globus Medical in a report released on Thursday, August 27th. Zacks Research analyst Team now expects that the medical device company will post earnings of $1.37 per share for the quarter, up from their prior forecast of $1.22. Zacks Research has a "Strong-Buy" rating on the stock. The consensus estimate for Globus Medical's current full-year earnings is $4.99 per share. Zacks Research also issued estimates for Globus Medical's FY2028 earnings at $5.88 EPS.

Globus Medical (NYSE:GMED - Get Free Report) last released its earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.24. The firm had revenue of $789.61 million during the quarter, compared to analyst estimates of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The business's revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the business earned $0.86 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS.

GMED has been the topic of a number of other research reports. Royal Bank Of Canada cut their target price on Globus Medical from $120.00 to $115.00 and set an "outperform" rating on the stock in a research note on Monday, July 13th. Stifel Nicolaus dropped their price objective on Globus Medical from $95.00 to $80.00 and set a "hold" rating for the company in a report on Wednesday, July 8th. UBS Group began coverage on Globus Medical in a research report on Tuesday, July 28th. They issued a "neutral" rating and a $82.00 price objective on the stock. Wells Fargo & Company decreased their target price on Globus Medical from $103.00 to $99.00 and set an "overweight" rating for the company in a research report on Friday, August 7th. Finally, Needham & Company LLC boosted their target price on shares of Globus Medical from $114.00 to $117.00 and gave the company a "buy" rating in a research note on Friday, May 8th. Three research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $101.77.

Globus Medical Price Performance

Shares of NYSE GMED opened at $83.03 on Monday. The company has a market cap of $11.15 billion, a P/E ratio of 21.24, a PEG ratio of 1.34 and a beta of 0.95. Globus Medical has a 1 year low of $54.15 and a 1 year high of $101.40. The firm has a 50-day simple moving average of $81.13 and a two-hundred day simple moving average of $84.59.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in GMED. California State Teachers Retirement System grew its stake in Globus Medical by 7,827.7% in the second quarter. California State Teachers Retirement System now owns 10,326,607 shares of the medical device company's stock valued at $815,905,000 after purchasing an additional 10,196,347 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Globus Medical by 4.5% during the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company's stock valued at $656,831,000 after buying an additional 328,217 shares during the last quarter. Invesco Ltd. lifted its position in shares of Globus Medical by 1,235.2% during the fourth quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company's stock valued at $339,322,000 after buying an additional 3,595,339 shares during the last quarter. Bank of Montreal Can boosted its holdings in shares of Globus Medical by 15,317.1% in the 4th quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company's stock valued at $294,519,000 after buying an additional 3,351,380 shares in the last quarter. Finally, Sculptor Capital LP boosted its holdings in shares of Globus Medical by 1.9% in the 1st quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company's stock valued at $263,477,000 after buying an additional 58,000 shares in the last quarter. 95.16% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director David D. Davidar sold 25,000 shares of Globus Medical stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the transaction, the director directly owned 510,175 shares of the company's stock, valued at $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Stephen T. Zarrilli sold 25,000 shares of Globus Medical stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the transaction, the director directly owned 25,000 shares in the company, valued at approximately $2,176,000. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 18.38% of the stock is currently owned by corporate insiders.

Globus Medical News Summary

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Broad upward revisions to earnings estimates: Zacks Research raised its FY2026 EPS forecast to $4.97 from $4.74 and its FY2027 forecast to $5.06 from $4.75. It also increased estimates for several upcoming quarters, including Q3 2026, Q1 and Q2 2027, Q3 2027, and Q1 and Q2 2028. The revisions suggest stronger expected profitability and support the stock’s bullish outlook. Zacks maintains a “Strong-Buy” rating. MarketBeat Globus Medical estimates report
• Positive Sentiment: Analysts see substantial upside: The average Wall Street price target implies approximately 25% potential appreciation for GMED. Although price targets are not always reliable, the article notes that analysts’ agreement in raising earnings estimates is a more constructive signal for the shares. Wall Street analysts believe Globus Medical could rally
• Positive Sentiment: Recent operating momentum provides support: Globus Medical’s latest quarterly results exceeded analyst expectations, with EPS of $1.34 versus a $1.10 consensus estimate and revenue of $789.6 million versus $782.9 million expected. Revenue rose 5.9% year over year, reinforcing the case for the higher forward estimates.
• Neutral Sentiment: Favorable investment-style coverage: Zacks highlighted GMED as a top-ranked momentum stock and compared it with Integer for value investors. These articles may improve visibility but do not represent new company fundamentals or a formal rating change. Globus Medical is a top-ranked momentum stock

About Globus Medical

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source